Using IL-17s for the Treatment of Psoriasis in 2024: A Roundtable Discussion

Authors

  • Susan Poelman, MD
  • Anatoli Freiman, MD

Abstract

The anti-IL-17 class is not only highly effective in treating psoriasis, but also other comorbidities associated with type 2 inflammation. Data presented by Dr. Kim Papp at the European Academy of Dermatology and Venerology in 2022 shows that brodalumab (Siliq), in particular, can effectively treat psoriasis even among patients for whom other IL-23- and IL-17-targeting biologics don’t work or have lost effectiveness over time. However, Brodalumab’s black box warning can be a prescribing barrier, especially among new-to-practice physicians. In this roundtable discussion, Dr Anatoli Freiman and Dr Susan Poelman, who both have wide clinical and research expertise in biologic therapies for psoriasis, share how they weigh clinical and real-world data of IL-17 cytokine inhibitors (secukinumab, ixekizumab, & bimekizumab) and IL-17 receptor antagonists (brodalumab) when treating psoriasis. 

Author Biographies

Susan Poelman, MD

Dr. Poelman is a Clinical Associate Professor at the University of Calgary and is co-director of Beacon Dermatology. She completed her master’s degree and medical school at the University of Calgary and residency at McGill University and the University of British Columbia. She has been in practice in dermatology for over 14 years. She currently serves as president of the Canadian HS Foundation and is actively involved in clinical research trials. She has been an invited speaker at national and international meetings and has served on the board of directors for the Canadian Dermatology Association, Women’s Dermatologic Society and the Alberta Society of Dermatology. 

Anatoli Freiman, MD

Dr. Anatoli Freiman is a Toronto dermatologist specializing in medical, surgical and cosmetic dermatology. He completed medical school training at McGill University and dermatology residency at McGill University and the University of Toronto. Dr. Freiman is an author and medical educator with many publications in dermatology and is a frequent lecturer at medical conferences. He is the chair of the Canadian Dermatology Association Sun Protection Program and is an expert on many editorial and advisory boards. Dr. Freiman is the Medical Director of the Toronto Dermatology Centre, a comprehensive dermatology clinic in Toronto.

Downloads

Published

2024-04-16

How to Cite

1.
Poelman S, Freiman A. Using IL-17s for the Treatment of Psoriasis in 2024: A Roundtable Discussion. Can Dermatol Today [Internet]. 2024 Apr. 16 [cited 2024 Jul. 15];5(s04):2–7. Available from: https://canadiandermatologytoday.com/article/view/5-s04-Poelman_et_al

Issue

Section

Articles